Angiomax Effective in Heart Attack Patients
Posted on: Friday, 26 October 2007, 09:00 CDT
The Medicines Company has reported superior clinical outcomes and fewer cardiac deaths in heart attack patients undergoing angioplasty compared to a more complex treatment regimen for its anti-clotting agent Angiomax in a global trial.
The Horizons AMI trial compared Angiomax to heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in more than 3,600 patients presenting with a heart attack. Horizons AMI demonstrated the efficacy of Angiomax in angioplasty patients with the most severe form of heart attack, ST-elevation myocardial infarction.
At 30 days, compared to heparin plus GPI, Angiomax reduced the incidence of net adverse clinical events, a composite of major adverse cardiac events or major bleeding, by 24%; curbed major bleeding by 40%; demonstrated comparable rates of major adverse cardiac events and reduced the incidence of cardiac-related mortality by 38%.
John Kelley, president and chief operating officer of Medicines Company, said: "The Horizon AMI results clearly demonstrate better clinical outcomes with Angiomax in heart attack patients. Findings from multiple global studies are remarkably consistent and show Angiomax improves outcomes across the entire spectrum of patients treated in the cardiac cath lab. Given these results, we anticipate greater uptake of Angiomax by physicians worldwide."
Source: Datamonitor
Related Articles
- Statins May Worsen Symptoms in Some Cardiac Patients
- Statins May Worsen Symptoms In Some Cardiac Patients
- New Analysis Suggests That Improvements in Kidney Function in Patients Treated With Lipitor Strongly Correlate With a Reduced Risk of Major Cardiovascular Events
- Brigham and Women's Hospital and Celera Publish Results Demonstrating That Carriers of a Variant of the LPA Gene Have More Than Two-Fold Higher Risk of Major Cardiovascular Events and That This Risk is Eliminated By Aspirin Therapy
- ORLive Presents: Minimally Invasive Lobectomy for Lung Cancer, Procedure Helps Patients Recover Quicker, With Better Long-Term Outcomes
- Hypothermia May Benefit Cardiac Patients: Study
- Cardiac and Vascular Surgery Associates Reports Multiple Successes Recovering Patients' Hearts With ABIOMED's AB5000 Support
- Pair of Major Attacks in Baghdad Kill 30
- 30 Killed in Pair of Major Attacks in Iraq
- Pfizer's Norvasc Demonstrates Significant Reductions in Major Cardiovascular Events in Patients With Coronary Artery Disease
 |
 |
User Comments (0)
RSS Feeds